Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $11.67 in the prior trading day, Avanos Medical Inc (NYSE: AVNS) closed at $11.45, down -1.89%. In other words, the price has decreased by -$1.89 from its previous closing price. On the day, 0.55 million shares were traded. AVNS stock price reached its highest trading level at $11.735 during the session, while it also had its lowest trading level at $11.431.
Ratios:
Our goal is to gain a better understanding of AVNS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.10. For the most recent quarter (mrq), Quick Ratio is recorded 1.36 and its Current Ratio is at 2.38. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.15.
On May 22, 2023, CL King started tracking the stock assigning a Buy rating and target price of $31.
Stephens Downgraded its Overweight to Equal-Weight on August 04, 2021, whereas the target price for the stock was revised from $60 to $45.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’25 when Holbrook Kerr sold 15,000 shares for $11.00 per share. The transaction valued at 165,014 led to the insider holds 83,860 shares of the business.
Holbrook Kerr bought 15,000 shares of AVNS for $165,014 on Nov 18 ’25. On Aug 13 ’25, another insider, BLACKFORD GARY, who serves as the Director of the company, bought 40,000 shares for $10.99 each. As a result, the insider paid 439,800 and bolstered with 40,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVNS now has a Market Capitalization of 531496480 and an Enterprise Value of 594696512. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.76 while its Price-to-Book (P/B) ratio in mrq is 0.68. Its current Enterprise Value per Revenue stands at 0.85 whereas that against EBITDA is 7.983.
Stock Price History:
The Beta on a monthly basis for AVNS is 1.07, which has changed by -0.27153558 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, AVNS has reached a high of $17.69, while it has fallen to a 52-week low of $9.30. The 50-Day Moving Average of the stock is -0.17%, while the 200-Day Moving Average is calculated to be -5.58%.
Shares Statistics:
The stock has traded on average 543.07K shares per day over the past 3-months and 615760 shares per day over the last 10 days, according to various share statistics. A total of 46.42M shares are outstanding, with a floating share count of 44.70M. Insiders hold about 3.71% of the company’s shares, while institutions hold 97.15% stake in the company. Shares short for AVNS as of 1764288000 were 2796444 with a Short Ratio of 5.15, compared to 1761868800 on 2378661. Therefore, it implies a Short% of Shares Outstanding of 2796444 and a Short% of Float of 8.53.
Earnings Estimates
The stock of Avanos Medical Inc (AVNS) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.23, with high estimates of $0.23 and low estimates of $0.23.
Analysts are recommending an EPS of between $0.9 and $0.9 for the fiscal current year, implying an average EPS of $0.9. EPS for the following year is $0.95, with 1.0 analysts recommending between $0.95 and $0.95.
Revenue Estimates
1 analysts predict $174.7M in revenue for. The current quarter. It ranges from a high estimate of $174.7M to a low estimate of $174.7M. As of. The current estimate, Avanos Medical Inc’s year-ago sales were $179.6MFor the next quarter, 1 analysts are estimating revenue of $169.5M. There is a high estimate of $169.5M for the next quarter, whereas the lowest estimate is $169.5M.
A total of 1 analysts have provided revenue estimates for AVNS’s current fiscal year. The highest revenue estimate was $695M, while the lowest revenue estimate was $695M, resulting in an average revenue estimate of $695M. In the same quarter a year ago, actual revenue was $687.8MBased on 1 analysts’ estimates, the company’s revenue will be $710M in the next fiscal year. The high estimate is $710M and the low estimate is $710M.
